Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

26.76 -1.23 (-4.39%)
Streaming Delayed Price Updated: 10:09 AM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
Via ACCESS Newswire
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Via ACCESS Newswire
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Via ACCESS Newswire
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
Via ACCESS Newswire
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
Via ACCESS Newswire
Moderna to Present at Upcoming Conferences in March 2025
Via ACCESS Newswire
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
Via ACCESS Newswire
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
Via ACCESS Newswire
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Via ACCESS Newswire
Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025
Via ACCESS Newswire
Moderna Announces Updates on Pandemic Influenza Program
Via ACCESS Newswire
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
Moderna to Present at Upcoming Conferences in December 2024
Via ACCESSWIRE
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
Via ACCESSWIRE
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Via ACCESSWIRE
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
Via ACCESSWIRE
Moderna to Present at Upcoming Conferences in November 2024
Via ACCESSWIRE
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Moderna Named a Top Employer by Science for Tenth Consecutive Year
Via ACCESSWIRE
Abbas Hussain Joins Moderna's Board of Directors
Via ACCESSWIRE
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Via ACCESSWIRE
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
MRNA Deadline: Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
IMPORTANT MRNA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
Via ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.